TP53 and colorectal cancer: These findings suggest that HJ-4 exerts its anti-tumor effects by activating the p53-mediated apoptotic pathway and inhibiting oncogenic signaling, highlighting its potential as a targeted therapeutic agent for colorectal cancer.